RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
34 hedge funds and large institutions have $50.9M invested in RVL Pharmaceuticals plc Ordinary Shares in 2018 Q4 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12M |
| 2 |
DM
Deerfield Management
New York
|
+$9.11M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$7.38M |
| 4 |
BC
Broadfin Capital
New York
|
+$4.23M |
| 5 |
BlackRock
New York
|
+$3.8M |
Top Sellers
RVLP Hedge Fund Activity: Q4 2018 in Review
34 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2018, worth a combined $50.9M.
Buyers outnumbered sellers: 34 funds opened new RVLP positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $12M.
- 34 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $50.9M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2018.
- 34 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2018 and 0 closed out, a net change of +34 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2018 was Great Point Partners, an estimated $12M added.
Based on aggregated 13F filings for Q4 2018.